RETINALAMIN - RETINA CELL ACTIVATOR

RETINALAMIN® refers to the pharmacotherapeutic stimulators of tissue regeneration. The mechanism of action is determined by the metabolic activity of Retinalamin®: the preparation activates eye tissue metabolism, normalizes the functions of cellular membranes, improves intracellular synthesis of protein, regulates the processes of lipid peroxide oxidation, and optimizes energy processes due to strengthened activity of Muller’s cells and glutamate inactivation. It improves the functional interaction between the pigment epithelium and outer segments of visual receptors, normalizes vascular permeability, prevents oxidative stress and excitotoxicity, improves metabolism in ocular tissues and blood flow in ocular vessels.

Retinalamin® activates retinal cells reserves increasing cell survivability and regenerative capacity when retina and optic nerve has been damaged. Retinalamin® increases metabolism and blood flow, optimizes vascular permeability in eyes. It improves and stabilizes visual functions (visual acuity, low-light eyesight, visual field extension). The data is supported by specific retina and optic nerve studies.

Pharmaceutical Company GEROPHARM is a sole manufacturer of original preparation Retinalamin®. The preparation is manufactured using the Company's own patented technology.

Retinoprotectors are agents that protect retina from damage caused by exogenous and endogenous forces thus safeguarding eyesight from getting worse. Searching for new agents for retinal protection is a complicated process which requires integrated efforts of therapists, biologists and pharmacologists. Special attention should be given to peptide preparations. The benefits of these preparations are tissue specificity, absence of significant side-effects, short-course treatment and long-term clinical effect. Retinalamin® is an example of successful preparation development based on these principles. The effecacy of Retinalamin® has been proven at the cellular and molecular levels. Retinal injuries may be caused by various factors and have different disease patterns, however, they are all accompanied by death of retinal neurons due to pathological processes with the similar molecular mechanisms. Among those mechanisms the most predominant one is excitotoxicity caused by overstimulation of glutamate receptors followed by the influx of calcium ions. Excessive Ca2+ concentration triggers processes of cell death via necrosis or apoptosis.

Pharmacodynamics:

Retinalamin® is a complex of water-soluble polypeptide fractions with the molecular weight of no more than 10,000 kDa. The agent has a stimulating effect on retinal photoreceptors and cellular elements, improves functional interaction between pigment epithelium and outer segments of photoreceptors, glial cells in patients with retinal dystrophy and accelerates recovery of light sensitivity processes in the retina. It normalizes vascular permeability, reduces local inflammation, and activates reparative processes in patients with diseases and traumas of the retina.

Usage:

• Compensated primary open-angle glaucoma,
• Diabetic retinopathy,
• Post-traumatic and post-inflammatory central retinal dystrophy (macular dystrophy),
• Central retinal dystrophy (macular dystrophy),
• Myopia (within comprehensive treatment),
• Central and peripheral tapetoretinal abiotrophy.

Contraindications:

• Individual hypersensitivity to any component of the medication;
• Children and adolescents under 18 years of age with compensated primary open-angle glaucoma, diabetic retinopathy, or myopia (due to a lack of efficacy and safety data);
• Infants under 12 months of age with post-traumatic or post-inflammatory central retinal dystrophy, or central and peripheral tapetoretinal abiotrophy;
• Pregnancy (due to a lack of data on its effects on fetal development);
• Breastfeeding.

Ingredients:

Each vial contains: bioregulator substance – Retinalamin 5 mg (complex of water-soluble polypeptide fractions),
excipient – Glycine 17 mg (stabilizer).

Dosage:

Dosage and administration schedule depend on the diagnosis and age and must be determined by a healthcare provider.

Adults with diabetic retinopathy, post-traumatic or post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 5–10 mg once daily. Treatment duration is 5–10 days; if necessary, the course may be repeated after 3–6 months.

Patients with compensated primary open-angle glaucoma: parabulbar or intramuscular injections of 5 mg once daily. Treatment duration is 10 days; if necessary, the course may be repeated after 3–6 months.

Patients with myopia: parabulbar injections of 5 mg once daily. Treatment duration is 10 days.
Recommended for use alongside angioprotectors and B vitamins.

Method of administration:

Retinalamin® is intended exclusively for injection: intramuscular or parabulbar (into the tissues surrounding the eyeball). It must be administered only by a healthcare professional in a clinical setting. Temporary visual impairment is possible after the parabulbar injection: you should refrain from driving and operating machinery until clear vision is restored.

How to reconstitute Retinalamin®:

The lyophilizate is reconstituted in a solvent (1-2 ml water for injection, saline, or 0.5% procaine (Novocaine) solution). The prepared solution must be used immediately.

How long does it take to work?

Retinalamin® stimulates tissue repair, meaning its therapeutic effect develops gradually. While cellular metabolism improves early in the cycle, visual stabilization and subjective improvements are typically noticed toward the end of the course or after its completion. Continuous and progressive improvement is standard for peptide therapy, so immediate results should not be expected.

Form release:

1 vial contains:
Active substance: Retinalamin® (a complex of water-soluble polypeptide fractions of bovine retina) 5 mg;
Excipient: Glycine 17 mg.
10 vials per pack

Storage conditions:

Store in a protected from light place, at a temperature of 2–20 °C.

Disclaimer:

This information is for educational purposes only and must not be considered medical advice. Always consult a qualified healthcare professional for accurate diagnosis, personalized dosage and treatment monitoring.

Guaranteed authenticity and quality:

100% Original from GEROPHARM (Russian Federation)

Development and production:

GEROPHARM (Russian Federation)

St. Petersburg Institute of Bioregulation and Gerontology